O'Brien Greene & Co. Inc Acurx Pharmaceuticals, Inc. Transaction History
O'Brien Greene & Co. Inc
- $289 Million
- Q2 2025
A detailed history of O'Brien Greene & Co. Inc transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, O'Brien Greene & Co. Inc holds 60,000 shares of ACXP stock, worth $268,200. This represents 0.01% of its overall portfolio holdings.
Number of Shares
60,000Holding current value
$268,200% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ACXP
# of Institutions
31Shares Held
3.68MCall Options Held
100Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ2.04MShares$9.14 Million6.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA529KShares$2.37 Million0.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$1.64 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$654,4250.0% of portfolio
-
Morgan Stanley New York, NY106KShares$474,7180.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $51.7M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...